CVRx reports Q3 revenue $3.4M (+241% YoY); repays $20M loan

CVRx, Inc.

2022-Q3 EPS reported -$4.66 revenue$9,378,000

Q3 revenue $3.4M (241% YoY increase); U.S. HF revenue $2.5M vs $140K prior year.
Net loss $6.1M ($0.30/share) vs $3.2M ($9.56/share) prior year; cash $170.9M.
Fully repaid $20M Horizon loan on Nov 3, including fees total $21.3M.
FY2021 guidance: revenue $13.3-13.9M; Q4 revenue expected $3.9-4.5M.
Filed three PMA Supplement submissions for Barostim platform; FDA approval expected H1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.